Ivosidenib for cholangiocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Nov 2025: Trial started, NCT07260175
  2. 3 Dec 2025: Trial registered, NCT07260175

The trials

NCT07260175: Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

State
Under way
Phase
Phase 2
People
40 planned
Started
18 Nov 2025
Primary completion
Dec 2030
Arms
Ivosidenib maintenance
Results
None posted
  1. 18 Nov 2025: Trial started
  2. 3 Dec 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Tibsovo.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.